Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy

<i>Background and Objectives</i>: Thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) is used to treat acute ischemic stroke. Dabigatran is a reversible thrombin inhibitor approved for stroke prevention in patients with nonvalvular atrial fibrillation. In such...

Full description

Bibliographic Details
Main Authors:	Ilga Kikule, Alise Baborikina, Iveta Haritoncenko, Guntis Karelis
Format:	Article
Language:	English
Published:	MDPI AG 2022-09-01
Series:	Medicina
Subjects:	ischemic stroke thrombolysis idarucizumab dabigatran antidote intracerebral hematoma
Online Access:	https://www.mdpi.com/1648-9144/58/10/1355

Similar Items

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
by: Valentin Held, et al.
Published: (2016-10-01)

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
by: Jameel Abdulrehman, et al.
Published: (2021-07-01)

Intravenous Thrombolysis After Reversal of Dabigatran With Idarucizumab in Acute Ischemic Stroke: A Case Report
by: Dan Xie, et al.
Published: (2021-12-01)

The new way of Dabigatran reversal – Idarucizumab
by: Erwin Ciechański, et al.
Published: (2019-02-01)

The new way of Dabigatran reversal – Idarucizumab
by: Erwin Ciechański, et al.
Published: (2019-02-01)

Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
by: Gorana Vukorepa, et al.
Published: (2020-01-01)

Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
by: Sergio Agosti, et al.
Published: (2017-08-01)

Idarucizumab for Dabigatran Reversal-full Cohort Analysis (RE-VERSE AD Study)
by: Esme Ekizoğlu
Published: (2018-06-01)

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
by: Sié P
Published: (2016-05-01)

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke
by: Maren Hieber, et al.
Published: (2019-03-01)

Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report
by: António Tralhão, et al.
Published: (2017-09-01)

The Riga East University Hospital Stroke Registry—An Analysis of 4915 Consecutive Patients with Acute Stroke
by: Guntis Karelis, et al.
Published: (2021-06-01)

Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
by: Jhih-Wei Dai, et al.
Published: (2023-05-01)

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
by: Waldemar Kafke, et al.
Published: (2016-06-01)

[Budget impact analysis of idarucizumab for the management of patients treated with dabigatran in emergency / urgent situations in Italy]
by: Andrea Belisari, et al.
Published: (2016-06-01)

The first experience with thrombolytic therapy for cerebral infarction in the Russian Federation after the use of idarucizumab
by: E. V. Pudov, et al.
Published: (2020-02-01)

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting
by: Nicolas Gendron, et al.
Published: (2020-12-01)

Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma
by: Gail Edwards, et al.
Published: (2018-02-01)

Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study
by: Masahiro Yasaka, et al.
Published: (2023-10-01)

The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports
by: Tomić Milan
Published: (2020-01-01)

Hemorragia digestiva grave de origen oscuro resuelta con idarucizumab
by: Enrique Rodríguez-de-Santiago, et al.

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran
by: Giannandrea D, et al.
Published: (2019-05-01)

Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study
by: Nils Kuklik, et al.
Published: (2023-07-01)

Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series
by: Senta Frol, et al.
Published: (2021-11-01)

Idarucizumab for a traumatic head injury patient taking dabigatran
by: Shuhei Maruyama, et al.
Published: (2018-10-01)

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
by: Hu TY, et al.
Published: (2016-02-01)

Retrospective Observational Study of Patients With Subdural Hematoma Treated With Idarucizumab
by: Eiichi Suehiro, et al.
Published: (2023-11-01)

Dabigatran Plasma Measurement to Guide the Management of Acute Bleeding and Thrombotic Complications
by: Maurizio Tala, et al.
Published: (2018-09-01)

Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01)

Systemic Thrombolytic Therapy for Ischemic Stroke in the Course of Anticoagulants
by: L. Kh.-B. Akhmatkhanova, et al.
Published: (2021-11-01)

Two Dabigatran Fast Reversals in a 4-month Period – a Case Report
by: Vítor Fagundes, et al.
Published: (2019-12-01)

Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report
by: Toshiyuki Ohtani, et al.
Published: (2019-12-01)

Idarucizumab in High-risk Thoracic Surgery
by: R L�pez Vilella, et al.
Published: (2018-04-01)

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
by: Proietti M, et al.
Published: (2018-08-01)

Chronic Kidney Disease and Cerebrovascular Pathology: Incidence and Functional Outcomes in Riga East University Hospital
by: Violeta Zubkova, et al.
Published: (2024-01-01)

Successful use of idarucizumab for the management of intracranial hemorrhage in an elderly woman receiving dabigatran for stroke prevention in atrial fibrillation: A case report
by: Manoj Mashru, et al.
Published: (2018-10-01)

Intravenous Thrombolysis for Acute Ischemic Stroke in Patients With Recent Direct Oral Anticoagulant Use: A Systematic Review and Meta‐Analysis
by: Malik Ghannam, et al.
Published: (2023-12-01)

Decision-Making Process for the Management of Acute Stroke in Patients on Oral Anticoagulant: From Guidelines to Clinical Routine
by: Igor Sibon, et al.
Published: (2022-01-01)

Dabigatran in the ischemic patient undergoing atrial fibrillation ablation
by: Roberto Spoladore
Published: (2018-10-01)

Thrombolytic therapy for ischemic stroke
by: Natalia Vyacheslavovna Pizova
Published: (2013-11-01)